Ipafricept: Phase Ib data

Top-line data from 17 evaluable patients with recurrent platinum-sensitive ovarian cancer in an open-label, dose-escalation, U.S. Phase Ib trial showed that 2, 4, 5 and 10 mg/kg IV ipafricept every 3 weeks plus carboplatin and paclitaxel led to an overall response rate (ORR) of 82.4%, including 6 complete responses and 8 partial responses, plus 3 cases of stable disease. Ipafricept was well tolerated with nausea, fatigue, neutropenia, alopecia, anorexia and vomiting reported as the most common treatment-related adverse events. Data will be presented at the American Society of Clinical Oncology meeting in Chicago (see BioCentury, June 16, 2014 & Sept. 8, 2014). ...